LONDON -(Dow Jones)- The European Medicines Agency, or EMA, Tuesday said it was formally notified by Pfizer Limited (PFE) of its decision to withdraw its application for an extension of the therapeutic indication for the centrally authorized medicine Macugen, pegaptanib sodium, 0.3 milligram, or mg, solution for injection. Pfizer submitted an application on June 14 to extend the marketing authorization for Macugen to include the treatment of visual impairment due to diabetic macular oedema in the indication.
